CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway

I. Villa, E. Mrak, A. Rubinacci, F. Ravasi, F. Guidobono

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system was evaluated as a potential target of CGRP anabolic activity on bone. Primary cultures of human osteoblast-like cells (hOB) express calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1, and, because CGRP stimulates cAMP (one of the modulators of OPG production in osteoblasts), it was investigated whether it affects OPG secretion and expression in hOB. CGRP treatment of hOB (10-11 M-10-7 M) dose-dependently inhibited OPG secretion with an EC50 of 1.08 × 10-10 M, and also decreased its expression. This action was blocked by the antagonist CGRP8-37. Forskolin, a stimulator of cAMP production, and dibutyryl cAMP also reduced the production of OPG. CGRP (10-8 M) enhanced protein kinase A (PKA) activity in hOB, and hOB exposure to the PKA inhibitor, H89 (2 × 10-6 M), abolished the inhibitory effect of CGRP on OPG secretion. Conditioned media from CGRP-treated hOB increased the number of multinucleated tartrate-resistant acid phosphatase-positive cells and the secretion of cathepsin K in human peripheral blood mononuclear cells compared with the conditioned media of untreated hOB. These results show that the cAMP/PKA pathway is involved in the CGRP inhibition of OPG mRNA and protein secretion in hOB and that this effect favors osteoclastogenesis. CGRP could thus modulate the balance between osteoblast and osteoclast activity, participating in the fine tuning of all of the bone remodeling phases necessary for the subsequent anabolic effect.

Original languageEnglish
JournalAmerican Journal of Physiology - Cell Physiology
Volume291
Issue number3
DOIs
Publication statusPublished - 2006

Fingerprint

Osteoprotegerin
Osteoblasts
Cyclic AMP-Dependent Protein Kinases
Cytoplasmic and Nuclear Receptors
Conditioned Culture Medium
Receptor Activity-Modifying Protein 1
Bone
Calcitonin Receptor-Like Protein
Cathepsin K
Anabolic Agents
Bone Remodeling
Osteoclasts
Colforsin
Protein Kinase Inhibitors
Acid Phosphatase
Cell culture
Osteogenesis
Human Activities
Modulators
Blood Cells

Keywords

  • Cathepsin K
  • Osteoclast
  • Protein kinase A
  • Receptor-activity-modifying proteins

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry
  • Physiology

Cite this

CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway. / Villa, I.; Mrak, E.; Rubinacci, A.; Ravasi, F.; Guidobono, F.

In: American Journal of Physiology - Cell Physiology, Vol. 291, No. 3, 2006.

Research output: Contribution to journalArticle

@article{d90485f78b6b4cf28c5944b252205d57,
title = "CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway",
abstract = "The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system was evaluated as a potential target of CGRP anabolic activity on bone. Primary cultures of human osteoblast-like cells (hOB) express calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1, and, because CGRP stimulates cAMP (one of the modulators of OPG production in osteoblasts), it was investigated whether it affects OPG secretion and expression in hOB. CGRP treatment of hOB (10-11 M-10-7 M) dose-dependently inhibited OPG secretion with an EC50 of 1.08 × 10-10 M, and also decreased its expression. This action was blocked by the antagonist CGRP8-37. Forskolin, a stimulator of cAMP production, and dibutyryl cAMP also reduced the production of OPG. CGRP (10-8 M) enhanced protein kinase A (PKA) activity in hOB, and hOB exposure to the PKA inhibitor, H89 (2 × 10-6 M), abolished the inhibitory effect of CGRP on OPG secretion. Conditioned media from CGRP-treated hOB increased the number of multinucleated tartrate-resistant acid phosphatase-positive cells and the secretion of cathepsin K in human peripheral blood mononuclear cells compared with the conditioned media of untreated hOB. These results show that the cAMP/PKA pathway is involved in the CGRP inhibition of OPG mRNA and protein secretion in hOB and that this effect favors osteoclastogenesis. CGRP could thus modulate the balance between osteoblast and osteoclast activity, participating in the fine tuning of all of the bone remodeling phases necessary for the subsequent anabolic effect.",
keywords = "Cathepsin K, Osteoclast, Protein kinase A, Receptor-activity-modifying proteins",
author = "I. Villa and E. Mrak and A. Rubinacci and F. Ravasi and F. Guidobono",
year = "2006",
doi = "10.1152/ajpcell.00354.2005",
language = "English",
volume = "291",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway

AU - Villa, I.

AU - Mrak, E.

AU - Rubinacci, A.

AU - Ravasi, F.

AU - Guidobono, F.

PY - 2006

Y1 - 2006

N2 - The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system was evaluated as a potential target of CGRP anabolic activity on bone. Primary cultures of human osteoblast-like cells (hOB) express calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1, and, because CGRP stimulates cAMP (one of the modulators of OPG production in osteoblasts), it was investigated whether it affects OPG secretion and expression in hOB. CGRP treatment of hOB (10-11 M-10-7 M) dose-dependently inhibited OPG secretion with an EC50 of 1.08 × 10-10 M, and also decreased its expression. This action was blocked by the antagonist CGRP8-37. Forskolin, a stimulator of cAMP production, and dibutyryl cAMP also reduced the production of OPG. CGRP (10-8 M) enhanced protein kinase A (PKA) activity in hOB, and hOB exposure to the PKA inhibitor, H89 (2 × 10-6 M), abolished the inhibitory effect of CGRP on OPG secretion. Conditioned media from CGRP-treated hOB increased the number of multinucleated tartrate-resistant acid phosphatase-positive cells and the secretion of cathepsin K in human peripheral blood mononuclear cells compared with the conditioned media of untreated hOB. These results show that the cAMP/PKA pathway is involved in the CGRP inhibition of OPG mRNA and protein secretion in hOB and that this effect favors osteoclastogenesis. CGRP could thus modulate the balance between osteoblast and osteoclast activity, participating in the fine tuning of all of the bone remodeling phases necessary for the subsequent anabolic effect.

AB - The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system was evaluated as a potential target of CGRP anabolic activity on bone. Primary cultures of human osteoblast-like cells (hOB) express calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1, and, because CGRP stimulates cAMP (one of the modulators of OPG production in osteoblasts), it was investigated whether it affects OPG secretion and expression in hOB. CGRP treatment of hOB (10-11 M-10-7 M) dose-dependently inhibited OPG secretion with an EC50 of 1.08 × 10-10 M, and also decreased its expression. This action was blocked by the antagonist CGRP8-37. Forskolin, a stimulator of cAMP production, and dibutyryl cAMP also reduced the production of OPG. CGRP (10-8 M) enhanced protein kinase A (PKA) activity in hOB, and hOB exposure to the PKA inhibitor, H89 (2 × 10-6 M), abolished the inhibitory effect of CGRP on OPG secretion. Conditioned media from CGRP-treated hOB increased the number of multinucleated tartrate-resistant acid phosphatase-positive cells and the secretion of cathepsin K in human peripheral blood mononuclear cells compared with the conditioned media of untreated hOB. These results show that the cAMP/PKA pathway is involved in the CGRP inhibition of OPG mRNA and protein secretion in hOB and that this effect favors osteoclastogenesis. CGRP could thus modulate the balance between osteoblast and osteoclast activity, participating in the fine tuning of all of the bone remodeling phases necessary for the subsequent anabolic effect.

KW - Cathepsin K

KW - Osteoclast

KW - Protein kinase A

KW - Receptor-activity-modifying proteins

UR - http://www.scopus.com/inward/record.url?scp=33748413499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748413499&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00354.2005

DO - 10.1152/ajpcell.00354.2005

M3 - Article

VL - 291

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 3

ER -